Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Total Liabilities data on record, last reported at $74.4 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 22.79% year-over-year to $74.4 million; the TTM value through Sep 2025 reached $74.4 million, down 22.79%, while the annual FY2024 figure was $93.2 million, 18.5% down from the prior year.
  • Total Liabilities reached $74.4 million in Q3 2025 per ZNTL's latest filing, up from -$274.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $114.3 million in Q4 2023 and bottomed at -$274.5 million in Q2 2025.
  • Average Total Liabilities over 4 years is $73.1 million, with a median of $98.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: grew 15.18% in 2023, then plummeted 351.6% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $105.3 million in 2022, then rose by 8.56% to $114.3 million in 2023, then fell by 18.5% to $93.2 million in 2024, then decreased by 20.16% to $74.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $74.4 million in Q3 2025, -$274.5 million in Q2 2025, and $88.6 million in Q1 2025.